Muscle actin is polyubiquitinylated in vitro and in vivo and targeted for breakdown by the E3 ligase MuRF1
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Muscle atrophy prevails in numerous diseases (cancer cachexia, renal failure, infections, etc. ), mainly results from elevated proteolysis, and is accelerated by bed rest. This largely contributes to increased health costs. Devising new strategies to prevent muscle wasting is a major clinical challenge. The ubiquitin proteasome system (UPS) degrades myofibrillar proteins, but the precise mechanisms responsible for actin breakdown are surprisingly poorly characterized. We report that chimeric flag‐actin was destabilized and polyubiquitinylated in stably transfected C2C12 myotubes treated with the catabolic agent dexa‐methasone (1 μM) and that only proteasome inhibitors blocked its breakdown. Actin polyubiquitinylation was also detected in wild‐type C2C12 myotubes and human muscle biopsies from control participants and patients with cancer. The muscle‐specific E3 ubiquitin ligase MuRF1 is up‐regulated in catabolic conditions and polyubiquitinylates components of the thick filament. We also demonstrate that recombinant GST‐MuRF1 physically interacted and polyubiquitinylated actin in vitro and that MuRF1 is a critical component for actin breakdown, since MuRF1 siRNA stabilized flag‐actin. These data identify unambiguously the abundant contractile protein actin as a target of the UPS in skeletal muscle both in vitro and in vivo , further supporting the need for new strategies blocking specifically the activation of this pathway in muscle wasting conditions.—Polge, C., Heng, A.‐E., Jarzaguet, M., Ventadour, S., Claustre, A., Combaret, L., Béchet, D., Matondo, M., Uttenweiler‐Joseph, S., Monsarrat, B., Attaix, D., Taillandier, D. Muscle actin is polyubiquitinylated in vitro and in vivo and targeted for breakdown by the E3 ligase MuRF1. FASEB J. 25, 3790–3802 (2011). www.fasebj.org
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of ubiquitin ligases required for skeletal muscle atrophy.
Bodine, S. C., Latres, E., Baumhueter, S., Lai, V. K.-M., Nunez, L., Clarke, B. A., Poueymirou, W. T., Panaro, F. J., Na, E., Dharmarajan, K., et al. (2001) · Science · doi:10.1126/science.1065874 · Cited by 3,521 · cited 1×
“atrophy induces rapid muscle wasting (29), and not”
BackgroundSandri, M., Sandri, C., Gilbert, A., Skurk, C., Calabria, E., Picard, A., Walsh, K., Schiaffino, S., Lecker, S. H., & Goldberg, A. L. (2004) · Cell · doi:10.1016/s0092-8674(04)00400-3 · Cited by 3,012 · cited 1×
“The glucocorticoid analog Dex is commonly used to induce a catabolic state in C2C12 myotubes (23), and similar observations were observed in Dex-treated fa-C2C12 myotubes (Supplemental Fig.”
ResultMultiple types of skeletal muscle atrophy involve a common program of changes in gene expression
Lecker, S. H., Jagoe, R. T., Gilbert, A., Gomes, M., Baracos, V., Bailey, J., Price, S. R., Mitch, W. E., & Goldberg, A. L. (2004) · The FASEB Journal · doi:10.1096/fj.03-0610com · Cited by 1,539
Skeletal muscle hypertrophy and atrophy signaling pathways
Glass, D. J. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.04.018 · Cited by 1,106 · cited 1×
“Furthermore, although this E3 is consistently recruited in numerous animal models of muscle atrophy (26), a nonsignificant increase of MuRF1 mRNA was also previously reported in Dex-treated C2C12 myotubes, in contrast to L6 cells (27).”
ResultThe E3 Ligase MuRF1 Degrades Myosin Heavy Chain Protein in Dexamethasone-Treated Skeletal Muscle
Clarke, B. A., Drujan, D., Willis, M. S., Murphy, L. O., Corpina, R. A., Burova, E., Rakhilin, S. V., Stitt, T. N., Patterson, C., Latres, E., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.09.009 · Cited by 683 · cited 4×
“, troponin I, MHCs, and telethonin (3, 7, 18, 28).”
BackgroundResultInfluential
Cited by
Mechanisms regulating skeletal muscle growth and atrophy
Schiaffino, S., Dyar, K. A., Ciciliot, S., Blaauw, B., & Sandri, M. (2013) · The FEBS Journal · doi:10.1111/febs.12253 · Cited by 1,492
Skeletal muscle atrophy and the E3 ubiquitin ligases MuRF1 and MAFbx/atrogin-1
Bodine, S. C., & Baehr, L. M. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00204.2014 · Cited by 1,113
Glucocorticoid-Induced Skeletal Muscle Atrophy
Schakman, O., Kalista, S., Barbé, C., Loumaye, A., & Thissen, J. P. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.05.036 · Cited by 705
Protein breakdown in muscle wasting: Role of autophagy-lysosome and ubiquitin-proteasome
Sandri, M. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.04.023 · Cited by 689
Muscle type and fiber type specificity in muscle wasting
Ciciliot, S., Rossi, A. C., Dyar, K. A., Blaauw, B., & Schiaffino, S. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.05.016 · Cited by 623
Bodine, S. C. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.06.011 · Cited by 389
Myostatin/activin pathway antagonism: molecular basis and therapeutic potential
Han, H. Q., Zhou, X., Mitch, W. E., & Goldberg, A. L. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.05.019 · Cited by 314
Lach-Trifilieff, E., Minetti, G. C., Sheppard, K., Ibebunjo, C., Feige, J. N., Hartmann, S., Brachat, S., Rivet, H., Koelbing, C., Morvan, F., et al. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.01307-13 · Cited by 306
Bindels, L. B., Beck, R., Schakman, O., Martin, J. C., De Backer, F., Sohet, F. M., Dewulf, E. M., Pachikian, B. D., Neyrinck, A. M., Thissen, J.-P., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037971 · Cited by 278
Metastatic cancers promote cachexia through ZIP14 upregulation in skeletal muscle
Wang, G., Biswas, A. K., Ma, W., Kandpal, M., Coker, C., Grandgenett, P. M., Hollingsworth, M. A., Jain, R., Tanji, K., Lόpez-Pintado, S., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0054-2 · Cited by 188
“For MG132 treatment following Polge et al, 2011 64 , 3-day differentiated C2C12 cells expressing Zip14 (Adeno-Zip14) were treated with 50μM ZnCl 2 for 24 hours, and then treated with either vehicle (DMSO) or MG132 (50μM) for 3 hours prior to harvest for immunoblot analysis.”
Protein breakdown in cancer cachexia
Sandri, M. (2016) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2015.11.002 · Cited by 134
“Thus far, MuRF1 ubiquitinates several muscle structural proteins, including troponin I [57], myosin heavy chains [58, 59], actin [60],”
BackgroundNutritional strategies to counteract muscle atrophy caused by disuse and to improve recovery
Magne, H., Savary-Auzeloux, I., Rémond, D., & Dardevet, D. (2013) · Nutrition Research Reviews · doi:10.1017/s0954422413000115 · Cited by 78
Skeletal muscle atrogenes: From rodent models to human pathologies
Taillandier, D., & Polge, C. (2019) · Biochimie · doi:10.1016/j.biochi.2019.07.014 · Cited by 66
Self-citationLi, F., Li, X., Peng, X., Sun, L., Jia, S., Wang, P., Ma, S., Zhao, H., Yu, Q., & Huo, H. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.4615 · Cited by 40
“Furthermore, MuRF1 ubiquitinates a number of structural proteins in the muscle including actin (64), myosin heavy chains (65,66), troponin I (67), myosin binding protein C and myosin light chains 1 and 2 (68).”
Metadata
- Authors
- Polge, C., Heng, A., Jarzaguet, M., Ventadour, S., Claustre, A., Combaret, L., Béchet, D., Matondo, M., Uttenweiler‐Joseph, S., Monsarrat, B., Attaix, D., & Taillandier, D.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2011-07-15
- Volume
- 25
- Issue
- 11
- Pages
- 3790-3802
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2133847359
- Cited by
- 146
- References
- 5
- FWCI
- 5.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.